Developers could face surge in clinical trial lawsuits

A surge in early-stage drug testing could well set the stage for a spike in lawsuits from patients who feel they've been hurt by the drugs they're volunteering to test, says a new report in The Wall Street Journal. The article starts off with the lawsuit brought by the family of Suzanne Davenport, who says she was hurt by an experimental medication for Parkinson's. Plaintiffs generally have a hard time making these charges stick, particularly as it's often difficult to link any worsening in their condition to the drug rather than the disease. Plaintiffs attorneys, though, are seeing plenty of fresh opportunities in the drug testing arena.

- read the report from The Wall Street Journal

Related Articles:
Report: FDA lax in clinical trial oversight. Report
Financial conflicts raise questions over trial results. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.